Please assess the completion status of the following clinical trial:

Trial Title: Zinc Sulfate for Human Papillomavirus (HPV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Abnormal cytology of atypical squamous cells of undetermined significance (ASCUS) on Pap smear OR~* Low-grade squamous intra epithelial lesions (LSIL) on Pap smear OR~* Positive hrHPV on routine screening (positive HPV will be assumed to be high grade)~Exclusion Criteria:~* Patients who proceed to excisional procedures (loop electrosurgical excision procedure or cold knife conization)~* Pregnant patients~* Breastfeeding patients~* Immunocompromised patients

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Zinc Sulfate 220mg twice daily for three months.
- Placebo (Type: PLACEBO_COMPARATOR): Gelatin Placebo tablet twice daily for three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).